Free Trial

Organon & Co. (OGN) Competitors

Organon & Co. logo
$13.90 +0.01 (+0.04%)
Closing price 03:59 PM Eastern
Extended Trading
$13.90 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OGN vs. ELAN, RDY, CORT, AXSM, and LNTH

Should you buy Organon & Co. stock or one of its competitors? Organon & Co.'s main competitors and comparable companies include Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Corcept Therapeutics (CORT), Axsome Therapeutics (AXSM), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Organon & Co. compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Elanco Animal Health has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Organon & Co. has a net margin of 3.49% compared to Elanco Animal Health's net margin of -2.86%. Organon & Co.'s return on equity of 82.06% beat Elanco Animal Health's return on equity.

Company Net Margins Return on Equity Return on Assets
Elanco Animal Health-2.86% 8.80% 4.32%
Organon & Co. 3.49%82.06%6.03%

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Elanco Animal Health currently has a consensus target price of $29.75, indicating a potential upside of 11.01%. Organon & Co. has a consensus target price of $12.00, indicating a potential downside of 13.64%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, equities analysts plainly believe Elanco Animal Health is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elanco Animal Health
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Organon & Co. has higher revenue and earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$5.15B2.60-$232M-$0.30N/A
Organon & Co.$6.22B0.59$187M$0.7618.28

In the previous week, Elanco Animal Health had 8 more articles in the media than Organon & Co.. MarketBeat recorded 11 mentions for Elanco Animal Health and 3 mentions for Organon & Co.. Elanco Animal Health's average media sentiment score of 0.48 beat Organon & Co.'s score of 0.46 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elanco Animal Health
4 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Organon & Co.
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Elanco Animal Health beats Organon & Co. on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Dr. Reddy's Laboratories?

Organon & Co. (NYSE:OGN) and Dr. Reddy's Laboratories (NYSE:RDY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Organon & Co. has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 8.56% compared to Organon & Co.'s net margin of 3.49%. Organon & Co.'s return on equity of 82.06% beat Dr. Reddy's Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.3.49% 82.06% 6.03%
Dr. Reddy's Laboratories 8.56%7.91%5.29%

In the previous week, Organon & Co. had 2 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 3 mentions for Organon & Co. and 1 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 0.92 beat Organon & Co.'s score of 0.46 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dr. Reddy's Laboratories
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

77.4% of Organon & Co. shares are held by institutional investors. Comparatively, 3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 1.6% of Organon & Co. shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. pays an annual dividend of $0.08 per share and has a dividend yield of 0.6%. Dr. Reddy's Laboratories pays an annual dividend of $0.06 per share and has a dividend yield of 0.4%. Organon & Co. pays out 10.5% of its earnings in the form of a dividend. Dr. Reddy's Laboratories pays out 16.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Organon & Co. is clearly the better dividend stock, given its higher yield and lower payout ratio.

Organon & Co. presently has a consensus price target of $12.00, suggesting a potential downside of 13.64%. Dr. Reddy's Laboratories has a consensus price target of $492.90, suggesting a potential upside of 3,238.30%. Given Dr. Reddy's Laboratories' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Reddy's Laboratories is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Dr. Reddy's Laboratories
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17

Dr. Reddy's Laboratories has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.22B0.59$187M$0.7618.28
Dr. Reddy's Laboratories$3.58B3.44$456M$0.3739.91

Summary

Organon & Co. and Dr. Reddy's Laboratories tied by winning 9 of the 18 factors compared between the two stocks.

How does Organon & Co. compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Organon & Co. (NYSE:OGN) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Corcept Therapeutics currently has a consensus target price of $139.50, indicating a potential upside of 91.25%. Organon & Co. has a consensus target price of $12.00, indicating a potential downside of 13.64%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Corcept Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corcept Therapeutics
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Organon & Co. has higher revenue and earnings than Corcept Therapeutics. Organon & Co. is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$761.41M10.48$99.65M$1.2757.43
Organon & Co.$6.22B0.59$187M$0.7618.28

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Corcept Therapeutics has a net margin of 16.53% compared to Organon & Co.'s net margin of 3.49%. Organon & Co.'s return on equity of 82.06% beat Corcept Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Corcept Therapeutics16.53% 22.56% 17.83%
Organon & Co. 3.49%82.06%6.03%

Corcept Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

In the previous week, Corcept Therapeutics had 1 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Corcept Therapeutics and 3 mentions for Organon & Co.. Corcept Therapeutics' average media sentiment score of 0.60 beat Organon & Co.'s score of 0.46 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Corcept Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Organon & Co.
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Corcept Therapeutics beats Organon & Co. on 12 of the 16 factors compared between the two stocks.

How does Organon & Co. compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Organon & Co. (NYSE:OGN) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

In the previous week, Axsome Therapeutics had 18 more articles in the media than Organon & Co.. MarketBeat recorded 21 mentions for Axsome Therapeutics and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.46 beat Axsome Therapeutics' score of 0.22 indicating that Organon & Co. is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Axsome Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Organon & Co.
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 1.6% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Organon & Co. has a net margin of 3.49% compared to Axsome Therapeutics' net margin of -18.18%. Organon & Co.'s return on equity of 82.06% beat Axsome Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Axsome Therapeutics-18.18% -198.73% -22.03%
Organon & Co. 3.49%82.06%6.03%

Axsome Therapeutics currently has a consensus price target of $266.21, indicating a potential upside of 87.88%. Organon & Co. has a consensus price target of $12.00, indicating a potential downside of 13.64%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Axsome Therapeutics
1 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.86
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

Organon & Co. has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Axsome Therapeutics$638.50M11.67-$183.17M-$3.06N/A
Organon & Co.$6.22B0.59$187M$0.7618.28

Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Summary

Organon & Co. beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Organon & Co. compare to Lantheus?

Organon & Co. (NYSE:OGN) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 1.6% of Organon & Co. shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Organon & Co. has a beta of 1.53, indicating that its share price is 53% more volatile than the broader market. Comparatively, Lantheus has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

Lantheus has a net margin of 17.28% compared to Organon & Co.'s net margin of 3.49%. Organon & Co.'s return on equity of 82.06% beat Lantheus' return on equity.

Company Net Margins Return on Equity Return on Assets
Organon & Co.3.49% 82.06% 6.03%
Lantheus 17.28%29.26%15.40%

Lantheus has lower revenue, but higher earnings than Organon & Co.. Organon & Co. is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organon & Co.$6.22B0.59$187M$0.7618.28
Lantheus$1.54B4.31$233.56M$4.0625.02

In the previous week, Lantheus had 3 more articles in the media than Organon & Co.. MarketBeat recorded 6 mentions for Lantheus and 3 mentions for Organon & Co.. Lantheus' average media sentiment score of 0.87 beat Organon & Co.'s score of 0.46 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organon & Co.
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lantheus
2 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Organon & Co. presently has a consensus target price of $12.00, indicating a potential downside of 13.64%. Lantheus has a consensus target price of $107.44, indicating a potential upside of 5.76%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Organon & Co..

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organon & Co.
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80
Lantheus
0 Sell rating(s)
11 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.21

Summary

Lantheus beats Organon & Co. on 13 of the 16 factors compared between the two stocks.

Get Organon & Co. News Delivered to You Automatically

Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OGN vs. The Competition

MetricOrganon & Co.Pharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$3.65B$13.76B$7.83B$23.18B
Dividend Yield0.58%2.58%2.47%3.78%
P/E Ratio18.3029.0834.3229.41
Price / Sales0.607.748.003.24
Price / Cash2.4015.7421.0215.64
Price / Book4.815.194.764.04
Net Income$187M$2.88B$3.52B$1.08B
7 Day Performance0.36%-3.90%-5.35%-3.09%
1 Month Performance1.09%-3.99%-3.62%-1.21%
1 Year Performance84.29%-7.16%-0.62%5.64%

Organon & Co. Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OGN
Organon & Co.
1.5304 of 5 stars
$13.91
+0.0%
$12.00
-13.7%
+84.2%$3.65B$6.10B18.3010,000
ELAN
Elanco Animal Health
3.2058 of 5 stars
$26.82
+4.2%
$29.75
+10.9%
+27.1%$12.65B$4.72BN/A9,400
RDY
Dr. Reddy's Laboratories
3.8534 of 5 stars
$15.03
+0.8%
$492.90
+3,178.8%
+6.0%$12.33B$3.58B40.6327,527
CORT
Corcept Therapeutics
4.0532 of 5 stars
$75.03
+3.1%
$139.50
+85.9%
-3.4%$8.67B$761.41M62.38730
AXSM
Axsome Therapeutics
3.5532 of 5 stars
$133.96
+1.2%
$267.58
+99.7%
+1.4%$7.21B$638.50MN/A925

Related Companies and Tools


This page (NYSE:OGN) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners